{"success":true,"data":{"pressRelease":{"id":"25232","rtpr_id":"nPn2Tsb3ma","ticker":"ARMP","exchange":"NYSE American","all_tickers":["ARMP"],"title":"Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02","author":"PR Newswire","published_at":"2026-05-07T11:00:06.817Z","article_body":"Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02\n\nPR Newswire\n\nLOS ANGELES, May 7, 2026\n\nEnables more frequent FDA engagement, rolling Biologic License Application\nreview, and the potential for Accelerated Approval and Priority Review upon\nsuccessful clinical development\n\nAdvances AP-SA02 on a faster path to potential approval and patient access\n\nLOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE\nAmerican: ARMP) (\"Armata\" or the \"Company\"), a late clinical-stage\nbiotechnology company focused on the development of high-purity,\npathogen-specific bacteriophage therapeutics for the treatment of\nantibiotic-resistant and difficult-to-treat bacterial infections, today\nannounced that the U.S. Food and Drug Administration (the \"FDA\") has granted\nFast Track Designation to AP-SA02, the Company's intravenously administered\nStaphylococcus aureus (\"S. aureus\") multi-phage product candidate, for adjunct\ntreatment of complicated bacteremia caused by methicillin-sensitive S. aureus\n(\"MSSA\") or methicillin resistant S. aureus (\"MRSA\").\n\n(https://mma.prnewswire.com/media/884786/Armata_Logo.html)\n\n\"We are pleased to receive Fast Track designation from the FDA for AP-SA02,\nwhich marks another important milestone for this program and underscores both\nthe seriousness of complicated S. aureus bacteremia (\"SAB\") and the urgent\nneed for effective new treatment options,\" said Dr. Deborah Birx, Chief\nExecutive Officer of Armata Pharmaceuticals. \"This designation recognizes the\npotential of AP-SA02 to improve upon current standard of care treatment\noptions for complicated SAB, a common, extremely severe, and often deadly\ninfection, and highlights the strength of Armata's phage platform to deliver\ndifferentiated therapies for bacterial infections. As we advance toward the\ninitiation of our Phase 3 superiority study, anticipated to begin in the\nsecond half of 2026, we remain focused on executing efficiently and look\nforward to interacting more frequently with the FDA throughout the clinical\ndevelopment and review process, with the goal of bringing this novel\nantibacterial therapy to patients as quickly as possible.\"\n\nFast Track designation is intended to facilitate the development and expedite\nthe review of investigational therapies that treat serious conditions and fill\nan unmet medical need. The designation provides for more frequent interactions\nwith the FDA regarding all aspects of a designated drug's clinical development\nprogram, supporting a more efficient path to registration. Fast Track\ndesignation also allows for rolling review of a Biologics License Application\n(\"BLA\"), meaning completed sections may be submitted and reviewed on an\nongoing basis rather than waiting for the full application. Additionally, Fast\nTrack-designated programs may also be eligible for Accelerated Approval and\nPriority Review if supported by clinical data at the time of BLA submission,\nfurther supporting a faster path to potential approval and patient access. For\nmore information on the Fast Track designation, visit the FDA's official\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3894287307&u=https%3A%2F%2Fwww.fda.gov%2Fpatients%2Ffast-track-breakthrough-therapy-accelerated-approval-priority-review%2Ffast-track&a=FDA%27s+official+website)\n.\n\nAbout AP-SA02\nArmata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct\ntreatment of complicated Staphylococcus aureus bacteremia caused by\nmethicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus\n(MRSA). The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter,\nrandomized, double-blind, placebo-controlled, multiple ascending dose\nescalation study of the safety, tolerability, and efficacy of intravenous\nAP-SA02 in addition to best available antibiotic therapy (\"BAT\") compared to\nBAT alone (placebo) for the treatment of adults with complicated S. aureus\nbacteremia. Positive results\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3465826898&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025-302590906.html&a=Positive+results)\nfrom the Phase 2a diSArm study were highlighted in a late-breaking oral\npresentation at IDWeek 2025™ in October 2025\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3502959349&u=https%3A%2F%2Ffilecache.investorroom.com%2Fmr5ir_armatapharma%2F187%2FArmata_Dr_Loren_Miller_IDWeek_2025_Late-Breaking_Oral_Presentation.pdf&a=presentation+at+IDWeek+2025%E2%84%A2+in+October+2025)\n. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a\n$26.2 million Department of Defense (DoD) award, received through the Medical\nTechnology Enterprise Consortium (MTEC) and managed by the Naval Medical\nResearch Command (NMRC) – Naval Advanced Medical Development (NAMD) with\nfunding from the Defense Health Agency and Joint Warfighter Medical Research\nProgram. The Company plans to advance AP-SA02 into a Phase 3 superiority study\nin complicated S. aureus bacteremia, anticipated to initiate in the second\nhalf of 2026.\n\nAbout Armata Pharmaceuticals, Inc.\nArmata is a late clinical-stage biotechnology company focused on the\ndevelopment of high-purity pathogen-specific bacteriophage therapeutics for\nthe treatment of antibiotic-resistant and difficult-to-treat bacterial\ninfections using its proprietary bacteriophage-based technology. Armata is\ndeveloping and advancing a broad pipeline of natural and synthetic phage\ncandidates, including clinical candidates for Pseudomonas aeruginosa, S.\naureus, and other important pathogens. Armata is committed to advancing phage\ntherapy with drug development expertise that spans bench to clinic including\nin-house phage-specific current Good Manufacturing Practices (\"cGMP\")\nmanufacturing to support full commercialization.\n\nForward Looking Statements\nThis communication contains \"forward-looking\" statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. These statements relate to\nfuture events, results or to Armata's future financial performance and involve\nknown and unknown risks, uncertainties and other factors which may cause\nArmata's actual results, performance or events to be materially different from\nany future results, performance or events expressed or implied by the\nforward-looking statements. In some cases, you can identify these statements\nby terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"will,\"\n\"would\" or the negative of those terms, and similar expressions. These\nforward-looking statements reflect management's beliefs and views with respect\nto future events and are based on estimates and assumptions as of the date of\nthis communication and are subject to risks and uncertainties including risks\nrelated to Armata's development of bacteriophage-based therapies; Armata's\nplanned clinical trials; ability to staff and maintain its production\nfacilities under fully compliant cGMP; ability to meet anticipated milestones\nin the development and testing of the relevant product; ability to be a leader\nin the development of phage-based therapeutics; ability to achieve its vision,\nincluding improvements through engineering and success of clinical trials;\nability to successfully complete preclinical and clinical development of, and\nobtain regulatory approval of its product candidates and commercialize any\napproved products on its expected timeframes or at all; and Armata's estimates\nregarding anticipated operating losses, capital requirements and needs for\nadditional funds. Additional risks and uncertainties relating to Armata and\nits business can be found under the caption \"Risk Factors\" and elsewhere in\nArmata's filings and reports with the U.S. Securities and Exchange Commission\n(the \"SEC\"), including in Armata's Annual Report on Form 10-K, filed with the\nSEC on March 25, 2026, and in its subsequent filings with the SEC.\n\nArmata expressly disclaims any obligation or undertaking to release publicly\nany updates or revisions to any forward-looking statements contained herein to\nreflect any change in Armata's expectations with regard thereto or any change\nin events, conditions or circumstances on which any such statements are based.\n\nMedia Contacts:\n\nAt Armata:\nPierre Kyme\nir@armatapharma.com (mailto:ir@armatapharma.com)\n310-665-2928\n\nInvestor Relations:\nJoyce Allaire\nLifeSci Advisors, LLC\njallaire@lifesciadvisors.com (mailto:jallaire@lifesciadvisors.com)\n212-915-2569\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html\n(https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html)\n\nSOURCE Armata Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/884786/Armata_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2Tsb3ma","title":"Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02","author":"PR Newswire","ticker":"ARMP","created":"2026-05-07T11:00:06.817Z","tickers":["ARMP"],"exchange":"NYSE American","article_body":"Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02\n\nPR Newswire\n\nLOS ANGELES, May 7, 2026\n\nEnables more frequent FDA engagement, rolling Biologic License Application\nreview, and the potential for Accelerated Approval and Priority Review upon\nsuccessful clinical development\n\nAdvances AP-SA02 on a faster path to potential approval and patient access\n\nLOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE\nAmerican: ARMP) (\"Armata\" or the \"Company\"), a late clinical-stage\nbiotechnology company focused on the development of high-purity,\npathogen-specific bacteriophage therapeutics for the treatment of\nantibiotic-resistant and difficult-to-treat bacterial infections, today\nannounced that the U.S. Food and Drug Administration (the \"FDA\") has granted\nFast Track Designation to AP-SA02, the Company's intravenously administered\nStaphylococcus aureus (\"S. aureus\") multi-phage product candidate, for adjunct\ntreatment of complicated bacteremia caused by methicillin-sensitive S. aureus\n(\"MSSA\") or methicillin resistant S. aureus (\"MRSA\").\n\n(https://mma.prnewswire.com/media/884786/Armata_Logo.html)\n\n\"We are pleased to receive Fast Track designation from the FDA for AP-SA02,\nwhich marks another important milestone for this program and underscores both\nthe seriousness of complicated S. aureus bacteremia (\"SAB\") and the urgent\nneed for effective new treatment options,\" said Dr. Deborah Birx, Chief\nExecutive Officer of Armata Pharmaceuticals. \"This designation recognizes the\npotential of AP-SA02 to improve upon current standard of care treatment\noptions for complicated SAB, a common, extremely severe, and often deadly\ninfection, and highlights the strength of Armata's phage platform to deliver\ndifferentiated therapies for bacterial infections. As we advance toward the\ninitiation of our Phase 3 superiority study, anticipated to begin in the\nsecond half of 2026, we remain focused on executing efficiently and look\nforward to interacting more frequently with the FDA throughout the clinical\ndevelopment and review process, with the goal of bringing this novel\nantibacterial therapy to patients as quickly as possible.\"\n\nFast Track designation is intended to facilitate the development and expedite\nthe review of investigational therapies that treat serious conditions and fill\nan unmet medical need. The designation provides for more frequent interactions\nwith the FDA regarding all aspects of a designated drug's clinical development\nprogram, supporting a more efficient path to registration. Fast Track\ndesignation also allows for rolling review of a Biologics License Application\n(\"BLA\"), meaning completed sections may be submitted and reviewed on an\nongoing basis rather than waiting for the full application. Additionally, Fast\nTrack-designated programs may also be eligible for Accelerated Approval and\nPriority Review if supported by clinical data at the time of BLA submission,\nfurther supporting a faster path to potential approval and patient access. For\nmore information on the Fast Track designation, visit the FDA's official\nwebsite\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3894287307&u=https%3A%2F%2Fwww.fda.gov%2Fpatients%2Ffast-track-breakthrough-therapy-accelerated-approval-priority-review%2Ffast-track&a=FDA%27s+official+website)\n.\n\nAbout AP-SA02\nArmata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct\ntreatment of complicated Staphylococcus aureus bacteremia caused by\nmethicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus\n(MRSA). The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter,\nrandomized, double-blind, placebo-controlled, multiple ascending dose\nescalation study of the safety, tolerability, and efficacy of intravenous\nAP-SA02 in addition to best available antibiotic therapy (\"BAT\") compared to\nBAT alone (placebo) for the treatment of adults with complicated S. aureus\nbacteremia. Positive results\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3465826898&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025-302590906.html&a=Positive+results)\nfrom the Phase 2a diSArm study were highlighted in a late-breaking oral\npresentation at IDWeek 2025™ in October 2025\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682366-1&h=3502959349&u=https%3A%2F%2Ffilecache.investorroom.com%2Fmr5ir_armatapharma%2F187%2FArmata_Dr_Loren_Miller_IDWeek_2025_Late-Breaking_Oral_Presentation.pdf&a=presentation+at+IDWeek+2025%E2%84%A2+in+October+2025)\n. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a\n$26.2 million Department of Defense (DoD) award, received through the Medical\nTechnology Enterprise Consortium (MTEC) and managed by the Naval Medical\nResearch Command (NMRC) – Naval Advanced Medical Development (NAMD) with\nfunding from the Defense Health Agency and Joint Warfighter Medical Research\nProgram. The Company plans to advance AP-SA02 into a Phase 3 superiority study\nin complicated S. aureus bacteremia, anticipated to initiate in the second\nhalf of 2026.\n\nAbout Armata Pharmaceuticals, Inc.\nArmata is a late clinical-stage biotechnology company focused on the\ndevelopment of high-purity pathogen-specific bacteriophage therapeutics for\nthe treatment of antibiotic-resistant and difficult-to-treat bacterial\ninfections using its proprietary bacteriophage-based technology. Armata is\ndeveloping and advancing a broad pipeline of natural and synthetic phage\ncandidates, including clinical candidates for Pseudomonas aeruginosa, S.\naureus, and other important pathogens. Armata is committed to advancing phage\ntherapy with drug development expertise that spans bench to clinic including\nin-house phage-specific current Good Manufacturing Practices (\"cGMP\")\nmanufacturing to support full commercialization.\n\nForward Looking Statements\nThis communication contains \"forward-looking\" statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. These statements relate to\nfuture events, results or to Armata's future financial performance and involve\nknown and unknown risks, uncertainties and other factors which may cause\nArmata's actual results, performance or events to be materially different from\nany future results, performance or events expressed or implied by the\nforward-looking statements. In some cases, you can identify these statements\nby terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"will,\"\n\"would\" or the negative of those terms, and similar expressions. These\nforward-looking statements reflect management's beliefs and views with respect\nto future events and are based on estimates and assumptions as of the date of\nthis communication and are subject to risks and uncertainties including risks\nrelated to Armata's development of bacteriophage-based therapies; Armata's\nplanned clinical trials; ability to staff and maintain its production\nfacilities under fully compliant cGMP; ability to meet anticipated milestones\nin the development and testing of the relevant product; ability to be a leader\nin the development of phage-based therapeutics; ability to achieve its vision,\nincluding improvements through engineering and success of clinical trials;\nability to successfully complete preclinical and clinical development of, and\nobtain regulatory approval of its product candidates and commercialize any\napproved products on its expected timeframes or at all; and Armata's estimates\nregarding anticipated operating losses, capital requirements and needs for\nadditional funds. Additional risks and uncertainties relating to Armata and\nits business can be found under the caption \"Risk Factors\" and elsewhere in\nArmata's filings and reports with the U.S. Securities and Exchange Commission\n(the \"SEC\"), including in Armata's Annual Report on Form 10-K, filed with the\nSEC on March 25, 2026, and in its subsequent filings with the SEC.\n\nArmata expressly disclaims any obligation or undertaking to release publicly\nany updates or revisions to any forward-looking statements contained herein to\nreflect any change in Armata's expectations with regard thereto or any change\nin events, conditions or circumstances on which any such statements are based.\n\nMedia Contacts:\n\nAt Armata:\nPierre Kyme\nir@armatapharma.com (mailto:ir@armatapharma.com)\n310-665-2928\n\nInvestor Relations:\nJoyce Allaire\nLifeSci Advisors, LLC\njallaire@lifesciadvisors.com (mailto:jallaire@lifesciadvisors.com)\n212-915-2569\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html\n(https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html)\n\nSOURCE Armata Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/884786/Armata_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-07T11:00:06.8582909Z","server_sent_at_ms":1778151606858},"received_at":"2026-05-07T11:00:06.972Z","source_url":"https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html"},"analysis":{"id":"19751","press_release_id":"25232","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Armata Pharmaceuticals received FDA Fast Track Designation for AP-SA02, its lead intravenous phage therapy candidate targeting complicated Staphylococcus aureus bacteremia.\n\nThe designation enables more frequent FDA engagement and rolling review of the Biologics License Application, potentially accelerating the path to approval and patient access.\n\nManagement plans to initiate a Phase 3 superiority study in the second half of 2026, building on positive Phase 2a results and partial support from a $26.2M DoD award.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Fast Track designation streamlines the regulatory path for ARMP's lead asset AP-SA02."},"keyFigures":{"drugName":"AP-SA02","phaseOfTrial":"Phase 3 (anticipated to begin in the second half of 2026)","customDimensions":{"funding_amount":"$26.2 million","funding_source":"Department of Defense (DoD) award"}},"quotedText":"This designation recognizes the potential of AP-SA02 to improve upon current standard of care treatment options for complicated SAB, a common, extremely severe, and often deadly infection","namedEntities":{"people":[{"name":"Dr. Deborah Birx","role":"Chief Executive Officer"}],"products":["AP-SA02"],"companies":[{"name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Medical Technology Enterprise Consortium (MTEC)","relationship":"funding partner"},{"name":"Naval Medical Research Command (NMRC)","relationship":"funding partner"}],"dollarAmounts":[{"amount":"$26.2 million","context":"Department of Defense award supporting Phase 1b/2a development"}]},"materialImpact":{"score":3,"reasoning":"Fast Track designation for lead asset AP-SA02 de-risks the regulatory pathway and facilitates accelerated review, but it remains a process milestone rather than a binary approval or efficacy readout."},"tickerRelevance":{"others":[],"primary":"ARMP"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"regulatory-milestone","sectorWeight":"biotech"}},"event_type":"regulatory","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":3,"narrative":"Armata Pharmaceuticals received FDA Fast Track Designation for AP-SA02, its lead intravenous phage therapy candidate targeting complicated Staphylococcus aureus bacteremia.\n\nThe designation enables more frequent FDA engagement and rolling review of the Biologics License Application, potentially accelerating the path to approval and patient access.\n\nManagement plans to initiate a Phase 3 superiority study in the second half of 2026, building on positive Phase 2a results and partial support from a $26.2M DoD award.","key_figures":{"drugName":"AP-SA02","phaseOfTrial":"Phase 3 (anticipated to begin in the second half of 2026)","customDimensions":{"funding_amount":"$26.2 million","funding_source":"Department of Defense (DoD) award"}},"named_entities":{"people":[{"name":"Dr. Deborah Birx","role":"Chief Executive Officer"}],"products":["AP-SA02"],"companies":[{"name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Medical Technology Enterprise Consortium (MTEC)","relationship":"funding partner"},{"name":"Naval Medical Research Command (NMRC)","relationship":"funding partner"}],"dollarAmounts":[{"amount":"$26.2 million","context":"Department of Defense award supporting Phase 1b/2a development"}]},"model_name":"glm-4.7","prompt_hash":"sha256:f66160e0fe5301b2","schema_hash":"sha256:12363694422af5d9","created_at":"2026-05-07T20:32:13.488Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"regulatory-milestone","sectorWeight":"biotech"}},"durationMs":null,"modelName":"glm-4.7"}}